Archivio articoli scientifici spiegati

Ciao!

Qui di seguito troverai i riferimenti a tutti gli articoli scientifici affrontati finora nelle mie newsletter.

Non sei ancora iscritto?

PSILOCIBINA

Psilocybin therapy for females with anorexia nervosa: a phase 1, open-label feasibility study.
Peck, S.K., Shao, S., Gruen, T.et al. Psilocybin therapy for females with anorexia nervosa: a phase 1, open-label feasibility study. Nat Med 29, 1947–1953 (2023). https://doi.org/10.1038/s41591-023-02455-9 

Psilocybin-induced changes in cerebral blood flow are associated with acute and baseline inter-individual differences.
Rieser NM, Gubser LP, Moujaes F, et al. Psilocybin-induced changes in cerebral blood flow are associated with acute and baseline inter-individual differences. Sci Rep. 2023;13(1):17475. Published 2023 Oct 14. doi:10.1038/s41598-023-44153-z

Single-Dose Psilocybin Treatment for Major Depressive Disorder: A Randomized Clinical Trial.
Raison CL, Sanacora G, Woolley J, et al. Single-Dose Psilocybin Treatment for Major Depressive Disorder: A Randomized Clinical Trial. JAMA. 2023;330(9):843–853. doi:10.1001/jama.2023.14530

Psilocybin for treatment resistant depression in patients taking a concomitant SSRI medication.
Goodwin GM, Croal M, Feifel D, et al. Psilocybin for treatment resistant depression in patients taking a concomitant SSRI medication. Neuropsychopharmacology. 2023;48(10):1492-1499. doi:10.1038/s41386-023-01648-7

Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression.
Goodwin GM, Aaronson ST, Alvarez O, et al. Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. N Engl J Med. 2022;387(18):1637-1648. doi:10.1056/NEJMoa2206443

Psilocybin induces acute and persisting alterations in immune status in healthy volunteers: An experimental, placebo-controlled study. 
Mason NL, Szabo A, Kuypers KPC, et al. Psilocybin induces acute and persisting alterations in immune status in healthy volunteers: An experimental, placebo-controlled study. Brain Behav Immun. 2023;114:299-310. doi:10.1016/j.bbi.2023.09.004

Single-Dose Synthetic Psilocybin With Psychotherapy for Treatment-Resistant Bipolar Type II Major Depressive Episodes: A Nonrandomized Controlled Trial.
Aaronson ST, van der Vaart A, Miller T, et al. Single-Dose Synthetic Psilocybin With Psychotherapy for Treatment-Resistant Bipolar Type II Major Depressive Episodes: A Nonrandomized Controlled Trial. JAMA Psychiatry. Published online December 06, 2023. doi:10.1001/jamapsychiatry.2023.4685

Effect of chemically synthesized psilocybin and psychedelic mushroom extract on molecular and metabolic profiles in mouse brain.
Shahar, O., Botvinnik, A., Shwartz, A. et al. Effect of chemically synthesized psilocybin and psychedelic mushroom extract on molecular and metabolic profiles in mouse brain. Mol Psychiatry (2024). https://doi.org/10.1038/s41380-024-02477-w

Psilocybin-assisted psychotherapy for treatment resistant depression: A randomized clinical trial evaluating repeated doses of psilocybin.
Rosenblat JD, Meshkat S, Doyle Z, et al. Psilocybin-assisted psychotherapy for treatment resistant depression: A randomized clinical trial evaluating repeated doses of psilocybin. Med. 2024;5(3):190-200.e5. doi:10.1016/j.medj.2024.01.005

Psilocybin enhances insightfulness in meditation: a perspective on the global topology of brain imaging during meditation
Singer B, Meling D, Hirsch-Hoffmann M, et al. Psilocybin enhances insightfulness in meditation: a perspective on the global topology of brain imaging during meditation [published correction appears in Sci Rep. 2024 Apr 23;14(1):9328]. Sci Rep. 2024;14(1):7211. Published 2024 Mar 26. doi:10.1038/s41598-024-55726-x

The Impact of Psilocybin on High Glucose/Lipid-Induced Changes in INS-1 Cell Viability and Dedifferentiation.
Gojani EG, Wang B, Li D-P, Kovalchuk O, Kovalchuk I. The Impact of Psilocybin on High Glucose/Lipid-Induced Changes in INS-1 Cell Viability and Dedifferentiation. Genes. 2024; 15(2):183.

Low nonpsychedelic dosed of psilocybin for the therapy of MASLD.
Poster presentation at EASL 2024. Presenter: Martina Colognesi.

Psilocybin desynchronizes the human brain.
Siegel, J.S., Subramanian, S., Perry, D. et al. Psilocybin desynchronizes the human brain. Nature 632, 131–138 (2024). https://doi.org/10.1038/s41586-024-07624-5

Longitudinal experiences of Canadians receiving compassionate access to psilocybin-assisted psychotherapy.
de la Salle, S., Kettner, H., Thibault Lévesque, J. et al. Longitudinal experiences of Canadians receiving compassionate access to psilocybin-assisted psychotherapy. Sci Rep 14, 16524 (2024). https://doi.org/10.1038/s41598-024-66817-0

Co-administration of midazolam and psilocybin: differential effects on subjective quality versus memory of the psychedelic experience.
Nicholas, C.R., Banks, M.I., Lennertz, R.C. et al. Co-administration of midazolam and psilocybin: differential effects on subjective quality versus memory of the psychedelic experience. Transl Psychiatry 14, 372 (2024). https://doi.org/10.1038/s41398-024-03059-8

The impact of antidepressant discontinuation prior to treatment with psilocybin for treatment-resistant depression.
Marwood L, Croal M, Mistry S, et al. The impact of antidepressant discontinuation prior to treatment with psilocybin for treatment-resistant depression. J Psychiatr Res. Published online October 11, 2024. doi:10.1016/j.jpsychires.2024.10.009

Single-dose psilocybin alters resting state functional networks in patients with body dysmorphic disorder.
Xi Zhu et al. Genomic Press 2024 https://doi.org/10.61373/pp024r.0028

Compass Psychological Support Model for COMP360 Psilocybin Treatment of Serious Mental Health Conditions.
Kirlić, N., Lennard-Jones, M., Atli, M., Malievskaia, E., Modlin, N. L., Peck, S. K., … Koelpin, D. (2025). Compass Psychological Support Model for COMP360 Psilocybin Treatment of Serious Mental Health Conditions. American Journal of Psychiatry, 182(1), 126–132. https://doi.org/10.1176/appi.ajp.20230884

LSD

Effects of External Stimulation on Psychedelic State Neurodynamics.
Mediano PAM, Rosas FE, Timmermann C, et al. Effects of External Stimulation on Psychedelic State Neurodynamics. ACS Chem Neurosci. 2024;15(3):462-471. doi:10.1021/acschemneuro.3c00289

Neural complexity is increased after low doses of LSD, but not moderate to high doses of oral THC or methamphetamine.
Murray, C.H., Frohlich, J., Haggarty, C.J. et al. Neural complexity is increased after low doses of LSD, but not moderate to high doses of oral THC or methamphetamine. Neuropsychopharmacol. (2024). https://doi.org/10.1038/s41386-024-01809-2

Psychedelic LSD activates neurotrophic signal but fails to stimulate neural stem cells.
Dong, X., Lin, H., Li, Y. et al. Psychedelic LSD activates neurotrophic signal but fails to stimulate neural stem cells. Stem Cell Res Ther 15, 285 (2024). https://doi.org/10.1186/s13287-024-03909-8

MDMA

Co-use of MDMA with psilocybin/LSD may buffer against challenging experiences and enhance positive experiences.
Zeifman RJ, Kettner H, Pagni BA, et al. Co-use of MDMA with psilocybin/LSD may buffer against challenging experiences and enhance positive experiences. Sci Rep. 2023;13(1):13645. Published 2023 Aug 22. doi:10.1038/s41598-023-40856-5

MDMA-assisted therapy for moderate to severe PTSD: a randomized, placebo-controlled phase 3 trial.
Mitchell, J.M., Ot’alora G., M., van der Kolk, B.et al. MDMA-assisted therapy for moderate to severe PTSD: a randomized, placebo-controlled phase 3 trial. Nat Med 29, 2473–2480 (2023). https://doi.org/10.1038/s41591-023-02565-4 

MDMA-assisted psychotherapy for PTSD in adolescents: rationale, potential, risks, and considerations.
Kangaslampi, S., Zijlmans, J. MDMA-assisted psychotherapy for PTSD in adolescents: rationale, potential, risks, and considerations.Eur Child Adolesc Psychiatry (2023). https://doi.org/10.1007/s00787-023-02310-9 

Effects of MDMA-assisted therapy for PTSD on self-experience.
van der Kolk BA, Wang JB, Yehuda R, et al. Effects of MDMA-assisted therapy for PTSD on self-experience. PLoS One. 2024;19(1):e0295926. Published 2024 Jan 10. doi:10.1371/journal.pone.0295926

Methylone is a rapid-acting neuroplastogen with less off-target activity than MDMA.
Warner-Schmidt J, Stogniew M, Mandell B, Rowland RS, Schmidt EF, Kelmendi B. Methylone is a rapid-acting neuroplastogen with less off-target activity than MDMA. Front Neurosci. 2024;18:1353131. Published 2024 Feb 7. doi:10.3389/fnins.2024.1353131

Expert opinions on implementation of MDMA-assisted therapy in Europe: critical appraisal towards training, clinical practice, and regulation.
Herpers, J., Maximets, N., van Dongen, N. N. N., Zijlmans, J., & Vermetten, E. (2024). Expert opinions on implementation of MDMA-assisted therapy in Europe: critical appraisal towards training, clinical practice, and regulation. European Journal of Psychotraumatology, 15(1). https://doi.org/10.1080/20008066.2024.2378651

Acute effects of R-MDMA, S-MDMA, and racemic MDMA in a randomized double-blind cross-over trial in healthy participants.
Straumann, I., Avedisian, I., Klaiber, A. et al. Acute effects of R-MDMA, S-MDMA, and racemic MDMA in a randomized double-blind cross-over trial in healthy participants. Neuropsychopharmacol. (2024). https://doi.org/10.1038/s41386-024-01972-6

DMT - AYAHUASCA

N,N-dimethyltryptamine reduces infarct size and improves functional recovery following transient focal brain ischemia in rats.
Nardai S, László M, Szabó A, et al. N,N-dimethyltryptamine reduces infarct size and improves functional recovery following transient focal brain ischemia in rats. Exp Neurol. 2020;327:113245. doi:10.1016/j.expneurol.2020.113245

Psychological and physiological effects of extended DMT.
Luan LX, Eckernäs E, Ashton M, et al. Psychological and physiological effects of extended DMT. J Psychopharmacol. 2023;2698811231196877. doi:10.1177/02698811231196877

Overcoming the clinical challenges of traditional ayahuasca: a first-in-human trial exploring novel routes of administration of N,N-Dimethyltryptamine and harmine.
Dornbierer DA, Marten L, Mueller J, et al. Overcoming the clinical challenges of traditional ayahuasca: a first-in-human trial exploring novel routes of administration of N,N-Dimethyltryptamine and harmine. Front Pharmacol. 2023;14:1246892. Published 2023 Nov 27. doi:10.3389/fphar.2023.1246892

Acute dose-dependent effects and self-guided titration of continuous N,N-dimethyltryptamine infusions in a double-blind placebo-controlled study in healthy participants.
Erne, L., Vogt, S.B., Müller, L. et al. Acute dose-dependent effects and self-guided titration of continuous N,N-dimethyltryptamine infusions in a double-blind placebo-controlled study in healthy participants. Neuropsychopharmacol. (2024). https://doi.org/10.1038/s41386-024-02041-8

KETAMINA

Efficacy and safety of a 4-week course of repeated subcutaneous ketamine injections for treatment-resistant depression (KADS study): randomised double-blind active-controlled trial.
Loo C, Glozier N, Barton D, et al. Efficacy and safety of a 4-week course of repeated subcutaneous ketamine injections for treatment-resistant depression (KADS study): randomised double-blind active-controlled trial. The British Journal of Psychiatry. 2023:1-9. doi:10.1192/bjp.2023.79

At-home, telehealth-supported ketamine treatment for depression: Findings from longitudinal, machine learning and symptom network analysis of real-world data.
Mathai DS, Hull TD, Vando L, Malgaroli M. At-home, telehealth-supported ketamine treatment for depression: Findings from longitudinal, machine learning and symptom network analysis of real-world data. J Affect Disord. Published online May 27, 2024. doi:10.1016/j.jad.2024.05.131

Extended-release ketamine tablets for treatment-resistant depression: a randomized placebo-controlled phase 2 trial.
Glue, P., Loo, C., Fam, J. et al. Extended-release ketamine tablets for treatment-resistant depression: a randomized placebo-controlled phase 2 trial. Nat Med 30, 2004–2009 (2024). https://doi.org/10.1038/s41591-024-03063-x

MICRODOSING

The difference between ‘placebo group’ and ‘placebo control’: a case study in psychedelic microdosing.
Szigeti, B., Nutt, D., Carhart-Harris, R.et al. The difference between ‘placebo group’ and ‘placebo control’: a case study in psychedelic microdosing. Sci Rep 13, 12107 (2023). https://doi.org/10.1038/s41598-023-34938-7 

Trait mindfulness and personality characteristics in a microdosing ADHD sample: a naturalistic prospective survey study.
Haijen ECHM, Hurks PPM, Kuypers KPC. Trait mindfulness and personality characteristics in a microdosing ADHD sample: a naturalistic prospective survey study. Front Psychiatry. 2023;14:1233585. Published 2023 Oct 16. doi:10.3389/fpsyt.2023.1233585

Microdosing psychedelics and the risk of cardiac fibrosis and valvulopathy: Comparison to known cardiotoxins. 
Rouaud A, Calder AE, Hasler G. Microdosing psychedelics and the risk of cardiac fibrosis and valvulopathy: Comparison to known cardiotoxins. Journal of Psychopharmacology. 2024;0(0). doi:10.1177/02698811231225609

IBOGAINA

Magnesium–ibogaine therapy in veterans with traumatic brain injuries.
Cherian, K.N., Keynan, J.N., Anker, L.et al. Magnesium–ibogaine therapy in veterans with traumatic brain injuries. Nat Med (2024). https://doi.org/10.1038/s41591-023-02705-w 

PSICHEDELICI (mix)

Psychedelics promote plasticity by directly binding to BDNF receptor TrkB.
Moliner R, Girych M, Brunello CA, et al. Psychedelics promote plasticity by directly binding to BDNF receptor TrkB. Nat Neurosci. 2023;26(6):1032-1041. doi:10.1038/s41593-023-01316-5

Imprinting: expanding the extra-pharmacological model of psychedelic drug action to incorporate delayed influences of sets and settings.
Garel N, Thibault Lévesque J, Sandra DA, et al. Imprinting: expanding the extra-pharmacological model of psychedelic drug action to incorporate delayed influences of sets and settings. Front Hum Neurosci. 2023;17:1200393. Published 2023 Jul 18. doi:10.3389/fnhum.2023.1200393

History repeating: guidelines to address common problems in psychedelic science.
van Elk M, Fried EI. History repeating: guidelines to address common problems in psychedelic science. Ther Adv Psychopharmacol. 2023;13:20451253231198466. Published 2023 Sep 25. doi:10.1177/20451253231198466

Predicting the Intensity of Psychedelic-Induced Mystical and Challenging Experience in a Healthy Population: An Exploratory Post-Hoc Analysis.
Ko K, Carter B, Cleare AJ, Rucker JJ. Predicting the Intensity of Psychedelic-Induced Mystical and Challenging Experience in a Healthy Population: An Exploratory Post-Hoc Analysis. Neuropsychiatr Dis Treat. 2023;19:2105-2113. Published 2023 Oct 5. doi:10.2147/NDT.S426193

Extended difficulties following the use of psychedelic drugs: A mixed methods study.
Evans J, Robinson OC, Argyri EK, et al. Extended difficulties following the use of psychedelic drugs: A mixed methods study. PLoS One. 2023;18(10):e0293349. Published 2023 Oct 24. doi:10.1371/journal.pone.0293349

Drug–drug interactions involving classic psychedelics: A systematic review.
Halman A, Kong G, Sarris J, Perkins D. Drug–drug interactions involving classic psychedelics: A systematic review. Journal of Psychopharmacology. 2023;0(0). doi:10.1177/02698811231211219

Psychedelics and sexual functioning: a mixed-methods study.
Barba T, Kettner H, Radu C, et al. Psychedelics and sexual functioning: a mixed-methods study. Sci Rep. 2024;14(1):2181. Published 2024 Feb 7. doi:10.1038/s41598-023-49817-4

Psychedelics and the ‘inner healer’: Myth or mechanism?
Peill J, Marguilho M, Erritzoe D, et al. Psychedelics and the ‘inner healer’: Myth or mechanism? Journal of Psychopharmacology. 2024;0(0). doi:10.1177/02698811241239206

Psychiatric risks for worsened mental health after psychedelic use.
Marrocu A, Kettner H, Weiss B, Zeifman RJ, Erritzoe D, Carhart-Harris RL. Psychiatric risks for worsened mental health after psychedelic use. Journal of Psychopharmacology. 2024;38(3):225-235. doi:10.1177/02698811241232548

Longitudinal associations between psychedelic use and psychotic symptoms in the United States and the United Kingdom.
Honk L, Stenfors CUD, Goldberg SB, et al. Longitudinal associations between psychedelic use and psychotic symptoms in the United States and the United Kingdom. J Affect Disord. 2024;351:194-201. doi:10.1016/j.jad.2024.01.197

Mind over matter: the microbial mindscapes of psychedelics and the gut-brain axis.
Caspani G, Ruffell SGD, Tsang W, et al. Mind over matter: the microbial mindscapes of psychedelics and the gut-brain axis. Pharmacol Res. 2024;207:107338. doi:10.1016/j.phrs.2024.107338

5-Methoxy-2-aminoindane Reverses Diet-Induced Obesity and Improves Metabolic Parameters in Mice: A Potential New Class of Antiobesity Therapeutics.
Baraghithy S, Gammal A, Permyakova A, et al. 5-Methoxy-2-aminoindane Reverses Diet-Induced Obesity and Improves Metabolic Parameters in Mice: A Potential New Class of Antiobesity Therapeutics. ACS Pharmacol Transl Sci. 2024;7(8):2527-2543. Published 2024 Jul 30. doi:10.1021/acsptsci.4c00353

The association between diverse psychological protocols and the efficacy of psilocybin-assisted therapy for clinical depressive symptoms: a Bayesian meta-analysis.
Chen MH, Cheng SL, Kao YC, et al. The association between diverse psychological protocols and the efficacy of psilocybin-assisted therapy for clinical depressive symptoms: a Bayesian meta-analysis. Front Psychiatry. 2024;15:1439347. Published 2024 Aug 13. doi:10.3389/fpsyt.2024.1439347

Knowledge, attitudes, and concerns about psilocybin and MDMA as novel therapies among U.S. healthcare professionals.
Wang, E., Mathai, D.S., Gukasyan, N. et al. Knowledge, attitudes, and concerns about psilocybin and MDMA as novel therapies among U.S. healthcare professionals. Sci Rep 14, 28022 (2024). https://doi.org/10.1038/s41598-024-78736-1

Isolation of psychedelic-responsive neurons underlying anxiolytic behavioral states.
J. Muir et al.,Isolation of psychedelic-responsive neurons underlying anxiolytic behavioral states.Science386,802-810(2024).DOI:10.1126/science.adl0666

Integration of personal psychedelic experiences into clinical practice: A phenomenological study in mental health professionals.
Tadmor, N., Halperin, D., & Simon, G. (2025). Integration of personal psychedelic experiences into clinical practice: A phenomenological study in mental health professionals. Journal of Psychedelic Studies (published online ahead of print 2025). https://doi.org/10.1556/2054.2024.00372